In a randomized, double‑blind, crossover trial of 51 patients with life‑threatening cancer, a single high dose of psilocybin produced large, rapid and sustained reductions in clinician- and self-rated depression and anxiety and increased quality of life, meaning and optimism, with about 80% of participants showing clinically significant improvement at six months. The therapeutic effects were mediated by the intensity of mystical‑type experiences during the session and were corroborated by community observer ratings.
- Published
- Journal
- Journal of Psychopharmacology
- Authors
- Griffiths, R. R., Johnson, M. W.